The University of Chicago, 5841 S. Maryland Ave. MC 2030, Chicago, IL, 60637, USA.
Curr Neurol Neurosci Rep. 2019 Nov 13;19(11):87. doi: 10.1007/s11910-019-1000-5.
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that affects nearly 1 million people in the USA and has the potential to profoundly affect physical ability and income potential at a young age. Since a landmark paper was published in 2014, few studies have looked at differences in MS disease characteristics between African-American and Caucasian patients.
African-American patients often have a more severe MS disease course, as well as biomarker data which can portend a worse prognosis. While the sample sizes are usually quite small, subgroup analyses of African-American patients have been performed to evaluate efficacy of disease-modifying treatments as compared with the entire study population, made up of primarily Caucasians. In an era where we strive for personalized medicine, understanding racial differences in MS may help us better treat African-American patients in the future.
目的综述:多发性硬化症(MS)是一种中枢神经系统自身免疫性疾病,在美国影响着近 100 万人,且具有在年轻时严重影响身体能力和收入潜力的潜在风险。自 2014 年发表了一篇具有里程碑意义的论文以来,很少有研究关注非裔美国人和白种人患者之间 MS 疾病特征的差异。
最新发现:非裔美国患者的 MS 病程往往更为严重,生物标志物数据预示着预后更差。虽然样本量通常较小,但对非裔美国患者进行了亚组分析,以评估与主要由白种人组成的整个研究人群相比,疾病修正治疗的疗效。在我们努力追求个体化医学的时代,了解 MS 中的种族差异可能有助于我们将来更好地治疗非裔美国患者。